Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The treatment of vancomycin-resistant enterococcal (VRE) bacteraemia remains challenging. Daptomycin is a new antibiotic with bactericidal activity against VRE, but available clinical data are limited. METHODS: A retrospective study was performed on 98 adult patients with VRE bacteraemia admitted to two hospitals between September 2003 and December 2007 to compare the efficacy of daptomycin with that of linezolid. Multivariable analyses were performed to compare the microbiological and clinical outcomes of both groups. RESULTS: Out of 98 patients with VRE bacteraemia, 68 were treated with linezolid and 30 with daptomycin. Univariate analyses showed no significant differences between the groups regarding baseline demographic and clinical characteristics, severity of illness and co-morbidity. Daptomycin was associated with a trend towards a higher mortality rate (26.7% versus 20.6%), longer median duration of bacteraemia (3 days versus 2 days) and higher relapse rate (6.7% versus 2.9%), but these differences did not reach statistical significance (P > 0.2). Microbiological cure rates were 90% for the daptomycin group and 88.2% for the linezolid group (P = 0.92). CONCLUSIONS: Despite a trend towards worse outcomes, daptomycin was as effective as linezolid in treating VRE bacteraemia. A randomized clinical trial is needed to confirm these results.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mave et al 203 reported cure in 2 of 3 patients with E faecium IE with linezolid.”
In the citing paper
“The number of cases of vancomycin-resistant Enterococcus bacteremia was too small to draw significant conclusions about treatment response rates.”
In the citing paper
“Mave et al 203 compared daptomycin with linezolid for vancomycin-resistant Enterococcus bacteremia.Five patients had E faecium IE; 1 of 2 daptomycin-treated patients and 2 of 3 linezolid-treated patients survived.”
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Vancomycin-resistant enterococci (VRE) emerged in the late 1980s and resistance to vancomycin is now found in 60% of Enterococcus faecium isolates causing nosocomial bloodstream infections (BSIs) encountered in US healthcare institutions.(1) Two different meta-analyses have shown that vancomycin resistance is an indep…”
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Durack, D. T., Lukes, A. S., Bright, D. K., & Service, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90143-0 · Cited by 2,572
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
DiazGranados, C. A., Zimmer, S. M., Mitchel, K., & Jernigan, J. A. (2005) · Clinical Infectious Diseases · doi:10.1086/430909 · Cited by 459 · cited 2×
“Vancomycin-resistant enterococci (VRE) emerged in the late 1980s and resistance to vancomycin is now found in 60% of Enterococcus faecium isolates causing nosocomial bloodstream infections (BSIs) encountered in US healthcare institutions.1 Two different meta-analyses have shown that vancomycin resistance is an indepen…”
Hematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003) · Clinical Infectious Diseases · doi:10.1086/345744 · Cited by 428
Development of daptomycin for Gram-positive infections
Tally, F. P., & DeBruin, M. F. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.4.523 · Cited by 321
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Nosocomial Spread of Linezolid-Resistant, Vancomycin-Resistant Enterococcus faecium
Herrero, I. A., Issa, N. C., & Patel, R. (2002) · New England Journal of Medicine · doi:10.1056/nejm200203143461121 · Cited by 241
Quinupristin‐Dalfopristin and Linezolid: Evidence and Opinion
Eliopoulos, G. M. (2003) · Clinical Infectious Diseases · doi:10.1086/367662 · Cited by 169
Outcomes Associated With Vancomycin-Resistant Enterococci: A Meta-Analysis
Salgado, C. D., & Farr, B. M. (2003) · Infection Control & Hospital Epidemiology · doi:10.1086/502271 · Cited by 159
Novel agents for the treatment of resistant Gram-positive infections
Woodford, N. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.2.117 · Cited by 105
Segreti, J. A., Crank, C. W., & Finney, M. S. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.347 · Cited by 88
Laganas, V., Alder, J., & Silverman, J. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2682-2684.2003 · Cited by 87
Nasraway, S. A., Shorr, A. F., Kuter, D. J., O'Grady, N., Le, V. H., & Cammarata, S. (2003) · Clinical Infectious Diseases · doi:10.1086/379327 · Cited by 76
Ruggero, K. A., Schroeder, L. K., Schreckenberger, P. C., Mankin, A. S., & Quinn, J. P. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(03)00153-6 · Cited by 62
Potential Genetic Causes of Heterogeneity of Treatment Effects
Goldstein, D. B., Need, A. C., Singh, R., & Sisodiya, S. M. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.02.004 · Cited by 59
Jorgensen, J. H., Crawford, S. A., Kelly, C. C., & PATTERSON, J. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3760-3763.2003 · Cited by 52
Daptomycin in the Treatment of Bacteremia
Sakoulas, G., Golan, Y., Lamp, K. C., Friedrich, L. V., & Russo, R. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.012 · Cited by 50
Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia
Kvirikadze, N., Suseno, M. T., Vescio, T. M., Kaminer, L. S., & Singh, K. S. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540500434687 · Cited by 31
Smith, P. F., Booker, B. M., Ogundele, A., & Kelchin, P. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.02.015 · Cited by 31
Abb, J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.10.007 · Cited by 9
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Enterococcal Infection—Treatment and Antibiotic Resistance
Kristich, C. J., Rice, L. B., & Arias, C. A. (2014) · Europe PMC (PubMed Central) · Cited by 315
Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?
Cattoir, V., & Leclercq, R. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks469 · Cited by 234
Mishra, N. N., Bayer, A. S., Tran, T. T., Shamoo, Y., Mileykovskaya, E., Dowhan, W., Guan, Z., & Arias, C. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043958 · Cited by 168
Metadata
- Authors
- Mave, V., Garcia-Diaz, J., Islam, T., & Hasbun, R.
- Affiliations
- Tulane University (US)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Hasbun, R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05-07
- Volume
- 64
- Issue
- 1
- Pages
- 175-180
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2170330952
- Semantic Scholar
- 187b1296174d179f0623afc59e2c538690a24325
- Cited by
- 65
- References
- 27
- Citations by year
- 2025: 2 · 2023: 2 · 2022: 2 · 2019: 3 · 2017: 4 · 2016: 3 · 2015: 7 · 2014: 11 · 2013: 5 · 2012: 11
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- vancomycin-resistant enterococci, bacteremia, daptomycin, linezolid, antibiotic efficacy comparison, mortality, relapse, microbiological cure, bactericidal activity
- MeSH terms
- Linezolid, Acetamides, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Female, Humans, Male, Middle Aged, Retrospective Studies, Bacteremia, Treatment Outcome, Gram-Positive Bacterial Infections, Enterococcus, Daptomycin, Vancomycin Resistance, Oxazolidinones, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.